Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated CLL/SLL

NCT03788291 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT03788291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03788291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated CLL/SLL
Lead sponsor
University of Rochester
Phase
Phase 2
Overall status
Completed
Start date
March 25, 2019
Completion date
May 19, 2023
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll)